| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 01/24/2001 | CN1061036C Substituted pyrazolyl benzenesulfonamides for treating inflammation |
| 01/24/2001 | CN1060950C Medicine powder for hyperthyroidism and its preparing process |
| 01/23/2001 | US6177560 Direct esterification of the 17 hydroxyl group without prior protection of the free 11 hydroxy function. |
| 01/23/2001 | US6177454 Antidiabetic agents |
| 01/23/2001 | US6177444 Allosteric adenosine receptor modulators |
| 01/23/2001 | US6177429 Dihydropyrazine derivatives as NPY antagonists |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004156A1 Peptides that lower blood glucose levels |
| 01/18/2001 | WO2001004119A1 Amido spiropiperidines promote the release of growth hormone |
| 01/18/2001 | WO2001004089A1 Vitamin d3 analogs |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2000067779A3 Polymerized liposomes for the delivery of mammalian growth hormone |
| 01/18/2001 | WO2000056864A3 Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1) |
| 01/18/2001 | WO2000024360A8 Preparation and use of solidified oils |
| 01/18/2001 | CA2680437A1 Peptides that lower blood glucose levels |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/17/2001 | EP1068195A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067931A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067930A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067929A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | CN1280575A New tricyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 01/17/2001 | CN1280570A Substituted fused heterocyclic compounds |
| 01/17/2001 | CN1280483A Site-specitic preparation of polyethylene glycol-GRF conjujates |
| 01/17/2001 | CN1280126A Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation |
| 01/17/2001 | CN1280125A Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation |
| 01/16/2001 | US6174925 Reducing insulin resistance in humans in whom impaired glucose tolerance or non-insulin dependent diabetes mellitus have not presented but in whom there is increased risk of developing such conditions by administering sibutramine analogue |
| 01/16/2001 | US6174904 Treating glycometabolism disorders in mammals by administering therapeutically effective amount of an insulin sensitivity enhancer in combination with an .alpha.-glucosidase inhibitor |
| 01/16/2001 | CA2018818C Treatment of postmenopausal disorders |
| 01/11/2001 | WO2001081364A1 Estra-1,3,5(10)-triene derivatives |
| 01/11/2001 | WO2001002569A2 Human immune response molecules |
| 01/11/2001 | WO2001002399A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/11/2001 | WO2001002381A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/11/2001 | WO2001002379A1 Selective npy (y5) antagonists |
| 01/11/2001 | WO2001002012A1 Remedies for drug-resistant hypercalcemia |
| 01/11/2001 | WO2001001970A2 New uses potassium channel openers, such as the treatment of epilepsy |
| 01/11/2001 | WO2001001748A2 Peptide compounds that bind her2 |
| 01/11/2001 | WO2000062657A3 Improvement of t cell mediated immunity |
| 01/11/2001 | WO2000061608A3 Low-molecular inhibitors of complement proteases |
| 01/11/2001 | WO2000039278A8 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 01/11/2001 | CA2380866A1 Selective npy (y5) antagonists |
| 01/11/2001 | CA2378116A1 Human immune response molecules |
| 01/11/2001 | CA2376673A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/11/2001 | CA2373945A1 Remedies for drug-resistant hypercalcemia |
| 01/10/2001 | EP1066307A1 3',3'-n-bis-substituted macrolide lhrh antagonists |
| 01/10/2001 | EP1066304A1 Macrolide lhrh antagonists |
| 01/10/2001 | EP1066285A1 Antagonists of gonadotropin releasing hormone |
| 01/10/2001 | EP1066284A1 Benzo c]quinolizine derivatives and their use as 5 alpha-reductases inhibitors |
| 01/10/2001 | EP1066268A1 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists |
| 01/10/2001 | EP1066030A1 Topical hormonal composition with systemic effect |
| 01/10/2001 | CN1279689A Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/10/2001 | CN1279666A NPY antagonists |
| 01/09/2001 | US6172090 Side effect reduction by administering an insulin sensitivity enhancer such as pioglitazone hydrochloride with a biguanide such as metformin |
| 01/09/2001 | US6172089 Pharmaceutical composition |
| 01/09/2001 | US6172080 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/09/2001 | US6172052 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 01/04/2001 | WO2001000830A1 Sgip peptides |
| 01/04/2001 | WO2001000676A1 Somatostatin agonists |
| 01/04/2001 | WO2001000652A2 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS |
| 01/04/2001 | WO2001000618A1 Benzamide derivatives |
| 01/04/2001 | WO2001000603A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/04/2001 | WO2001000585A1 Pyrazolidinol compounds |
| 01/04/2001 | WO2001000244A2 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| 01/04/2001 | WO2001000227A1 Gonadotropin releasing hormone antagonist |
| 01/04/2001 | WO2000060082A3 Vesicle associated proteins |
| 01/04/2001 | WO2000052145A3 Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| 01/04/2001 | WO2000020358B1 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION |
| 01/04/2001 | CA2377721A1 Sgip peptides |
| 01/04/2001 | CA2377265A1 Somatostatin agonists |
| 01/04/2001 | CA2377200A1 Pyrazolidinol compounds |
| 01/04/2001 | CA2341974A1 Gonadotropin releasing hormone antagonist |
| 01/03/2001 | EP1065208A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/03/2001 | EP1064308A1 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| 01/03/2001 | EP1064298A2 Inhibitors of caspases |
| 01/03/2001 | EP1064015A2 Receptor derived peptides as modulators of receptor activity |
| 01/03/2001 | EP1063996A1 Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v 1a? and v 2? receptors |
| 01/03/2001 | EP1063990A1 Therapy of estrogen-associated disorders |
| 01/03/2001 | CN1278819A Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating and stress-related |
| 01/03/2001 | CN1278812A 2-aryl-3-aroylbenzo [b] thiophenes for treatment of estrin deficiency |
| 01/03/2001 | CN1278811A 2-Arylbenzo[b] thiophenes useful for the treatment of estrogen deprivtion syndrome |
| 01/03/2001 | CN1060173C Heterocyclic compound with activity against diabetes and preparation nad application of same |
| 01/03/2001 | CN1060080C Gynecological external use capsule |
| 01/02/2001 | US6169100 Pharmaceutical composition |
| 01/02/2001 | US6169099 Pharmaceutical composition |
| 01/02/2001 | US6169070 Mer receptor activation by gas6 |
| 01/02/2001 | US6168920 Extracellular adhesive proteins |
| 01/02/2001 | CA2187274C Treatment of partial growth hormone insensitivity syndrome |
| 01/02/2001 | CA2183313C Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase |
| 01/02/2001 | CA2027593C Composition with antiaggreting action on platelet, for therapeutic uses |
| 01/02/2001 | CA2013166C Suppression of parathyroid hormone synthesis and secretion |
| 01/02/2001 | CA1341162C Sbustituted aminomethyltetralins and their heterocyclic analogues |
| 12/28/2000 | WO2000078972A2 Regulation with binding cassette transporter protein abc1 |
| 12/28/2000 | WO2000078971A2 Atp binding cassette transporter protein abc1 popypeptides |
| 12/28/2000 | WO2000078953A2 Human transport proteins |
| 12/28/2000 | WO2000078952A2 Human rna metabolism proteins (rmep) |
| 12/28/2000 | WO2000078805A1 Peptide having preptin functionality |
| 12/28/2000 | WO2000078794A1 Cysteinyl protease inhibitors |
| 12/28/2000 | WO2000078765A2 CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |